NEW YORK (GenomeWeb) – Proteomics International said today it has entered a strategic alliance with CPR Pharma Services focused on clinical trials and related research.

Under the terms of the deal, Proteomics International will acquire 10 percent of CPR's share capital in exchange for 4 million of its shares. This transaction is subject to CPR shareholder approval and is scheduled to take place on March 5, 2018.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.